In May of 2013, Tamir received a decision from the SEC, revoking registration of the common stock of Tamir (Press release Tamir Biotechnology, FEB 5, 2014, View Source [SID:1234500377]). Broker-dealers have been prohibited from executing trades of Tamir common stock, and thus, public trading of Tamir’s stock ceased in early July of 2013. With a new management team in place, they are refocusing the science toward solving difficult antiviral problems (such as HPV and CMV). They believe in the potential efficacy of Onconase(r) for the treatment of viruses, so they continue work to obtain credible results.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!